Kimberly Monty Holzel > Goodwin > Boston, United States > Lawyer Profile
Goodwin Offices

100 NORTHERN AVENUE
BOSTON MA 02210
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Kimberly Monty Holzel

Position
Partner
Career
Kimberly Monty Holzel is a partner in Goodwin’s Financial Industry, Consumer Financial Services and Fintech practices. She advises banks and Fintech clients offering tech-enabled consumer financial services on compliance with consumer financial services laws. Kimberly works with payment services, blockchain and virtual currency companies on FinCEN’s money service business (MSB) regulations and anti-money laundering requirements. She also prepares banks, lenders and Fintech companies for supervision by financial services regulators and represents them in connection with state and federal regulatory investigations, examinations, and inquiries.
Prior to joining the firm, Kimberly worked for the US Consumer Financial Protection Bureau. During Kimberly’s four years at the CFPB, she headed examination teams at large financial institutions, among other responsibilities. The CFPB teams she led examined for compliance with, among other things, mortgage originations and servicing, fair lending laws, and consumer loan and consumer banking matters.
Education
JD, Boston College Law School (cum laude) / BA, Cornell University (with distinction)
Lawyer Rankings
Top Tier Firm Rankings
- Industry focus > Cannabis
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Dispute resolution > E-discovery
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- Intellectual property > Patents: litigation (full coverage)
- Real estate > Real estate
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- M&A/corporate and commercial > Shareholder activism
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- International trade and national security > CFIUS
- Finance > Commercial lending
- M&A/corporate and commercial > Corporate governance
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- International trade and national security > Customs, export controls and economic sanctions
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Intellectual property > Patents: litigation (International Trade Commission)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Healthcare > Service providers
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Real estate > Real estate finance
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Finance > Financial services regulation